Australia-based digital health technologies provider Adherium’s Smartinhaler has been selected for the European Union’s (EU) asthma initiatve, myAirCoach programme.
Europe’s key opinion leaders have selected Smartinhaler to evaluate the impact of digital health solutions on asthma control and exacerbations.
The myAirCoach programme is part of EU’s Horizon 2020 Framework for Research and Innovation, a program established with around €80bn that is available for over 7 years from 2014 to 2020.
The programme will evaluate whether home monitoring and mobile health (mHealth) systems can be used to predict asthma control and the occurrence of asthma exacerbations.
It will also engage in developing devices to enable patients manage their health through user-friendly tools, which will increase awareness of their clinical state, adherence and effectiveness of the medical treatment they follow.
According to Adherium, Smartinhaler is proved to reduce hospitalisation as showed in the results of the year-long STAAR study, which showed a significant reduction in hospital admissions over the course of one year.
Organisations involved in the myAirCoach project comprised of Imperial College London, University of Manchester and Leiden University Medical Center. It is expected to continue for the next one year.
Adherium will also distribute a range of products to the programme through three centres, including devices for inhaled medications produced by AstraZeneca and GSK.
Adherium Group CEO and founder Garth Sutherland said: “Successful disease management and prevention is only truly achieved by understanding the real-world complexity of our lives.
“The best way to do that is through rich data collected in the real world. By providing our innovative solutions to people with asthma, we can help people take the right medicine, at the right dose, at the right time and in the right way."